首页> 外文期刊>Gynecological surgery >Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate System: safety, tolerability, and ablation results in a closed abdomen setting
【24h】

Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate System: safety, tolerability, and ablation results in a closed abdomen setting

机译:经宫颈,子宫内超声引导的VizAblate系统对子宫肌瘤进行射频消融:安全性,耐受性和消融可导致腹部闭合

获取原文
       

摘要

This was a single-site cohort study to evaluate the safety of a new transcervical device (VizAblate?) combining real-time intrauterine sonography with radiofrequency (RF) ablation for the treatment of fibroids. Nineteen women with uterine fibroids received treatment with the VizAblate System in a closed abdomen setting prior to hysterectomy. Twelve of these subjects underwent an immediate abdominal hysterectomy after radiofrequency ablation (acute group), while the remaining seven underwent hysterectomy on post-ablation days?16 and 17 (subacute group). Uteri were sectioned and stained with the viability stain triphenyltetrazolium chloride (TTC) to quantify fibroid ablation dimensions and assess the serosa for thermal injury. Subjects in the subacute group were treated with the VizAblate System under conscious sedation; they provided pain and tolerability data for the interval from ablation through hysterectomy, and indicated overall procedural satisfaction. Twenty-two ablations ranging from 1.8 to 36.2?cm3 were created among 19 subjects within 20 fibroids and one region of adenomyosis. There were no complications or thermal serosal injury. For subjects in the subacute group receiving one ablation, the mean total procedure time was 25.8?±?6.0?min (range 18–32?min). All subjects in the subacute group were discharged within 2?h of the VizAblate procedure. For fibroids?≤?5?cm, 67.2%?±?27.0% of the fibroid volume was ablated (range 15–100%; median 75%). Transcervical RF ablation of fibroids under intrauterine sonographic guidance with the VizAblate system can be accomplished with a high degree of reliability and without adverse events.
机译:这是一项单点队列研究,旨在评估将新型宫腔内超声检查与实时子宫内超声检查结合射频消融治疗肌瘤的新型经颈器械(VizAblate?)的安全性。 19名子宫肌瘤妇女在子宫切除术前在封闭的腹部环境中接受了VizAblate系统治疗。这些受试者中有十二名在射频消融后立即进行了腹部子宫切除术(急性组),而其余七名在消融后第16天和第17天接受了子宫切除术(亚急性组)。子宫被切成薄片并用生存力染色剂氯化三苯四唑(TTC)染色,以量化子宫肌瘤消融尺寸并评估浆膜热损伤。亚急性组的受试者在有意识的镇静下接受了VizAblate系统的治疗;他们提供了从消融到子宫切除术之间的疼痛和耐受性数据,并显示了总体手术满意度。在20例肌瘤和一个子宫腺肌病区域中的19位受试者中创建了22个从1.8到36.2?cm 3 的消融。没有并发症或浆膜热损伤。对于亚急性组接受一次消融的受试者,平均总手术时间为25.8?±?6.0?min(18-32?min)。亚急性组中的所有受试者在VizAblate手术后2小时内出院。对于≤≤5?cm的肌瘤,消融了肌瘤体积的67.2%?±?27.0%(范围为15-100%;中位数为75%)。通过子宫内超声在VizAblate系统的引导下进行子宫肌瘤的射频射频消融可以高度可靠,并且没有不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号